Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The pharmacokinetics of trastuzumab are not well-known. The volume of distribution approximates serum volume (44 mL/kg). [54] The elimination route has not been clearly defined. In studies in ...